Tagged with Europe,

Hungary Hungary’s two largest pharma firms, Egis Pharmaceuticals and Gedeon Richter, are stepping up their biosimilars offering; providing the European market with more affordable biologic medicines and bolstering Hungary’s footprint in biologics R&D.   Biosimilars in Europe Over the past decade, over 80 biologic molecules have been launched worldwide. By 2020…

Hungary Like many of its European counterparts, Hungary is suffering from medicine shortages. Vaccines, vitamins, and orphan drugs are some of the most affected areas and oncology patients are now also at risk.   An Increasing Burden Over 14,000 types of pharmaceuticals are unavailable in Hungarian pharmacies, which is placing an…

Europe Awareness is growing of the dangers of healthcare-associated infections (HAIs) in Europe, and conversations are beginning to taking place around how to leverage data to combat these infections and antimicrobial resistance (AMR). A panel of experts from diverse backgrounds at the European Health Forum Gastein put their heads together to…

Hungary Hungarian patients currently experience longer wait times and more limited access to subsidised innovative medicines than their neighbours in Bulgaria and Slovakia.leading some organisations to urge the government to increase funding and shorten approval times.   According to the Hungarian Association of Innovative Pharma Manufacturers, since 2016 only 48 new…

Pharma Market Poland is by far the largest pharma market in the Central and Eastern Europe (CEE) region, with a total value of EUR 6.352 billion for 2017. The Czech Republic is in second place, followed by Romania and Hungary Made with Visme Infographic Maker     The CEE countries that exported…

Generics Christoph Stoller, general manager for Austria and Germany at Teva was recently elected president of Medicines for Europe, the continent-wide association for the generics and biosimilars industries. Stoller plans to focus his efforts on improving access to generics and biosimilars in Europe, as well as tackling the damaging issue of…

Oncology Cancer is on the rise in Hungary and survival rates are considerably lower than the European average. The country’s innovative pharma association has taken the initiative to suggest measures that it believes would drastically improve cancer mortality rates and quality of life for oncology patients.   Recent statistics show that…

Europe Christoph Stoller, the recently appointed president of Medicines for Europe, outlines the mission of his presidency, how the association and its members are working to tackle the issue of drug shortages across the continent, and the crucial importance of establishing a high-level dialogue between industry and governments. Adrian van den…

Europe Dentons Germany’s Peter Homberg outlines the key requirements that companies need to fulfil in order to import medical cannabis into Germany and how attitudes and legislation on the topic are shifting across Europe.   In order to import medicinal cannabis from another country to Germany, like many other countries, the…

Europe Janssen’s EMEA market access head Martin Price outlines the regulatory changes that need to be made for patients across Europe to better access cutting-edge cancer medicines.   Recent advances in medical science are the driving force behind the research and successful development of innovative cancer treatments in Europe. By targeting…

Janssen PharmaBoardroom recently sat down with Janssen EMEA head Kris Sterkens, who outlined the enduring importance of Europe to the global group, even with the emergence of Asian power markets such as China and the continuing significance of the USA. Read the full interview here.   Where Europe really does excel…

Europe European MidPharmas – R&D based pharmaceutical companies with annual revenues of between EUR 50 million and 5 billion – are having to be increasingly focused and resilient to succeed and fend off their inherent vulnerabilities according to a new report from specialist pharma and biotech consultancy Novasecta.   Focus 75…